Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | DHODH | Q02127 | 1/20 | 0.49 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.45 |
| ▸ | KMO | O15229 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL27623769 | 0.90 | NPC1 (0.66) | NPC1RAB9ASLC6A2SLC6A4DHODH | |
| SCHEMBL27848727 | 0.86 | NPC1 (0.58) | NPC1RAB9ASLC6A2SLC6A4DHODH | |
| SCHEMBL537001 | 0.86 | NPC1 (0.58) | NPC1RAB9ASLC6A2SLC6A4DHODH | |
| SCHEMBL18561699 | 0.86 | NPC1 (0.58) | NPC1RAB9ASLC6A2SLC6A4DHODH | |
| SCHEMBL15758248 | 0.84 | NPC1 (0.60) | NPC1RAB9ASLC6A2SLC6A4DHODH | |
| Acetone SCHEMBL28117313 | 0.82 | KMO (0.58) | HAO1KMOCYP2C9KMT2ASMN1; SMN2 | |
| SCHEMBL11290635 | 0.82 | KMO (0.58) | NPC1RAB9ADHODHHAO1KMO | |
| Fluoride SCHEMBL28559395 | 0.82 | NPC1 (0.58) | NPC1RAB9ASLC6A2SLC6A4DHODH | |
| Hydrogen Peroxide SCHEMBL28451101 | 0.82 | NPC1 (0.52) | NPC1RAB9ADHODHHAO1KMO | |
| SCHEMBL28751412 | 0.81 | NPC1 (0.54) | NPC1RAB9ASLC6A2SLC6A4DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404731-B2 | Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors | TRANSTECH PHARMA, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120196906-A1 | Substituted Imidazole Derivatives, Compositions, and Methods of Use as PTPase Inhibitors | TRANSTECH PHARMA, INC. (US) | 2012-08-02 | — | — | US | disclosed |
| CN-101374835-B | Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors | TRANSTECH PHARMA INC | 2012-04-25 | — | — | CN | disclosed |
| US-7723369-B2 | Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors | TRANSTECH PHARMA, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20100113331-A1 | Substituted Imidazole Derivatives, Compositions, and Methods of Use as PtPase Inhibitors | TRANSTECH PHARMA, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| CN-101374835-A | Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors | TRANSTECH PHARMA INC (US) | 2009-02-25 | — | — | CN | disclosed |
| EP-1991544-A2 | SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS PTPASE INHIBITORS | Transtech Pharma, Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| US-20070191385-A1 | Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors | VTV THERAPEUTICS LLC | 2007-08-16 | — | — | US | disclosed |
| WO-2007089857-A2 | SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS PTPASE INHIBITORS | TRANSTECH PHARMA, INC. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191385-A1 | Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors | PTP4A1, PTPRJ, PTP4A2 | NPC1 2905/4885RAB9A 2481/4885SLC6A2 2934/4885 |
| US-20100113331-A1 | Substituted Imidazole Derivatives, Compositions, and Methods of Use as PtPase Inhibitors | PTP4A1, PTPRJ, PTP4A2 | NPC1 2905/4885RAB9A 2481/4885SLC6A2 2934/4885 |
| US-20120196906-A1 | Substituted Imidazole Derivatives, Compositions, and Methods of Use as PTPase Inhibitors | PTP4A1, PTPRJ, PTP4A2 | NPC1 2905/4885RAB9A 2481/4885SLC6A2 2934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.